Long-Term Efficacy and Safety of Brogidirsen for Duchenne Muscular Dystrophy Unveiled at 2026 WMS Congress

Promising Results for Brogidirsen in Duchenne Muscular Dystrophy

In a significant presentation at the 2026 World Muscle Society Congress held in Hiroshima, Japan, NS Pharma, Inc. unveiled vital findings from a five-year clinical trial on Brogidirsen (NS-089/NCNP-02), a groundbreaking treatment for Duchenne Muscular Dystrophy (DMD). This investigational therapy targets specific genetic mutations affecting muscle function and shows great promise in altering the disease's progression.

Overview of the Clinical Trial

The presentation showcased data collected from an open-label extension of an investigator-initiated clinical trial carried out by the National Center of Neurology and Psychiatry (NCNP). This research focused on evaluating the long-term efficacy and safety of Brogidirsen in six participants over five years, particularly those with dystrophin gene mutations amenable to exon 44 skipping. The results signal a remarkable step forward in providing treatment options for DMD patients who have limited pathways available.

President of NS Pharma, Yukiteru Sugiyama, Ph.D., expressed optimism regarding the findings, stating, "The longer-term data demonstrates the potential for Brogidirsen to slow disease progression in DMD patients. Our commitment to advancing therapeutic innovations aims to offer patients more treatment options and renewed hope."

Key Findings from the Trial

The trial outcomes revealed several critical insights:
1. Maintenance of Motor Function: Most participants retained or improved their motor abilities, even among those who transitioned to non-ambulant during the study period. Notably, upper limb functionality was preserved across all participants.
2. Acceptable Safety Profile: Encouragingly, after five years of treatment with Brogidirsen, there were no serious side effects or allergic reactions reported. Participants did not discontinue the treatment due to adverse effects, reiterating the therapy's tolerability.
3. Comparison with Natural History: The functional outcomes observed in participants surpassed those typically expected based on the natural history of DMD.

These results are incredibly important as they indicate Brogidirsen's potential to alter the course of DMD for patients eligible for exon 44 skipping. Moreover, the extension of the ongoing trial aims to delve deeper into understanding long-term efficacy and safety aspects further.

The Road Ahead for Brogidirsen

Following this promising presentation, NS Pharma and its parent company, Nippon Shinyaku, are advancing toward a global Phase II study of Brogidirsen, aimed at expanding its accessibility to a broader patient population. This new study underscores the companies’ commitment to continue exploring the potential of Brogidirsen in transforming DMD treatment.

Understanding Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy, primarily affecting males, is a severe form of muscular dystrophy that results in progressive muscle weakness and loss. Patients with DMD often face challenges with mobility and may require wheelchair assistance during adolescence as muscle capabilities decline, eventually affecting respiratory and cardiac muscles, which can lead to severe complications.

About NS Pharma, Inc.

NS Pharma, based in Paramus, New Jersey, is a subsidiary of Nippon Shinyaku Co., Ltd., a company with over a century of experience in biopharmaceutical development. Committed to addressing rare diseases, NS Pharma focuses on delivering unparalleled care to individuals facing complex health challenges. Their dedication is evident in their continued efforts to innovate and improve therapeutic approaches for rare conditions like DMD.

To learn more about clinical trials or Duchenne Muscular Dystrophy, please visit ClinicalTrials.gov or Wespeakduchenne.com.